Aurora Cannabis and Canopy Growth Earnings Preview: What to Expect

Cannabis giants Aurora Cannabis and Canopy Growth are set to report their fiscal first-quarter results this week. Analysts expect Aurora Cannabis to report an EPS of -$0.01, with a revenue estimate of $52.6 million. Canopy Growth's EPS is expected to be -$0.07, with a revenue estimate of $107.2 million. Both companies are expected to post losses, but the revenue estimates suggest potential growth.

Title: Cannabis Giants Aurora Cannabis and Canopy Growth Set to Report Q1 Results

Cannabis giants Aurora Cannabis (ACB) and Canopy Growth (CGC) are scheduled to release their fiscal first-quarter (Q1) 2026 results this week. Analysts expect Aurora Cannabis to report an EPS of -$0.01, with a revenue estimate of $52.6 million. Canopy Growth's EPS is expected to be -$0.07, with a revenue estimate of $107.2 million. Both companies are expected to post losses, but the revenue estimates suggest potential growth.

Aurora Cannabis is anticipated to report its Q1 results on August 6, before the market opens. The Zacks Consensus Estimate for earnings and revenues is pegged at 18 cents per share and $70.88 million, respectively [1]. The earnings estimate indicates a whopping 263.6% growth year over year. The Zacks Consensus Estimate for quarterly revenues suggests a year-over-year increase of 5.4%. The consensus mark for fiscal 2026 revenues is pegged at $272.1 million, implying a rise of 7.6% year over year, and the same for EPS is pinned at 56 cents, suggesting a year-over-year improvement of 100% [1].

Aurora Cannabis is expected to report its results following a record-setting fiscal 2025 driven by its focused "medical-first" strategy. The upcoming results are expected to reflect sustained momentum in global medical cannabis sales, supported by expanded product offerings, ongoing international market penetration, and operational excellence [1]. Australia continues to be a key growth lever, where Aurora Cannabis recently expanded its IndiMed portfolio with the launch of TEMPO 22 cultivars, catering to rising patient demand for high-potency, value-segment medical cannabis [1].

Canopy Growth is scheduled to report earnings on August 8, before the market opens. The company is expected to post an EPS of -$0.09 and revenue of $47.1 million [2]. The company missed the consensus in the previous quarter, which the management attributed to lower revenue in Storz & Bickel and Poland and Australia medical businesses [2]. The softness continued into Q1 fiscal 2026 with Storz & Bickel direct-to-consumer sales declining over 50% during the 420 promotional events compared to last year [2].

Both companies have been facing regulatory headwinds in various markets, which have impacted their performance. Aurora Cannabis has been hurt by temporary regulatory headwinds in Poland, while Canopy Growth has seen softness in Storz & Bickel and Poland and Australia medical businesses [1, 2]. However, both companies remain optimistic about the long-term growth prospects in their respective markets.

Aurora Cannabis and Canopy Growth are expected to post losses in their Q1 results, but the revenue estimates suggest potential growth. Investors will be closely watching the results to gauge the companies' performance and future prospects. The upcoming results will provide valuable insights into the companies' ability to navigate regulatory challenges and capitalize on growth opportunities in the global medical cannabis market.

References
[1] https://finance.yahoo.com/news/aurora-cannabis-pre-q1-earnings-123000853.html
[2] https://seekingalpha.com/news/4478833-will-cannabis-giants-turn-green-this-quarter-heres-what-to-expect